Introduction
============

Primary Liver cancer is the sixth common cancer globally, after cancers of the lung, breast, colorectal, prostate and gastric^1^. However, the extremely poor prognosis for primary liver cancer makes it the second leading cause of cancer-related death globally (745,000 deaths, 9.1% of the total death)^2^. Despite the prevalence of liver cancer is more frequent in developing country, it is still a significant health burden in many parts of the developed regions, including North America and central Europe^3-5^. In contrast to stable or declining trends of other cancers in US (such as lung, breast, and colorectal cancers), the incidence and death rates of primary liver cancer increased rapidly among men and women in recent decades^6^. Unlike hepatitis B viral infection as the predisposing factor for liver cancer in Asian, the increasing incidence in American is largely attributed to infection of chronic hepatitis C virus (HCV)^7^. Other predominant risk factors included alcohol abuse, non-alcoholic fatty liver diseases (NAFLD), aflatoxin B1 exposure and diabetes mellitus^8,\ 9^. Histologically, the majority of liver cancer is either hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC), while combined hepatocellular carcinoma and cholangiocarcinoma is less common^10^. Currently, potentially curative therapies for liver cancer include liver transplantation, hepatic resection and radiofrequency ablation. However, these modalities are not readily available to advanced patients^11^. Though these treatments have shown modest improvement in overall survival in early stage disease, the 5-year relative survival for distant metastasis patients is still low (3.1%). As we all know, primary liver cancer preferentially metastasize to the portal vein and extrahepatic metastasis including lungs, bones, brain, lymph nodes, and adrenal glands^12-14^. Thus far, few detailed studies explored extrahepatic metastasis profiles due to rare data of liver cancer metastasis. Patterns of extrahepatic metastasis still need further clarification. Besides, it is unclear whether different metastatic sites would be translated into distinct clinical outcomes. Thus, it is crucial to elucidate the metastatic distribution for better treatments and survival benefits. Therefore, in the present study we retrospectively reviewed data from SEER population-based cancer registry, in an attempt to explore metastasis profiles of primary liver cancer. Furthermore, we analysed the clinical characteristics and prognosis according to their distinct metastatic sites. We sought to explore clinical and demographic differences among patients with primary liver cancer.

Methods
=======

Cohort population
-----------------

The Surveillance, Epidemiology, and End Results (SEER) Program is the largest publicly available cancer dataset and is maintained by the National Cancer Institute. The SEER population-based cancer registries contain information from various locations and sources throughout the United States, which represents approximately 28% of the U.S. population. Data was based on Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying). The detailed population selection procedure was summarized in Figure [1](#F1){ref-type="fig"}. Briefly, we included patients aged ≥18 years with diagnosis of primary liver cancer between 2010 and 2012 identified from the SEER database. We excluded patients whose metastasis status and follow-up information was unknown. We performed a retrospective cohort study through the SEER database to identify the distant metastasis pattern of primary liver cancer. This database only includes metastasis to the bone, brain, liver, lung and distant lymph nodes at the time of diagnosis since 2010. The study was approved by the review board of the First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China.

Statistical analysis
--------------------

We used descriptive statistics to summary demographic and clinical characteristics of population. Chi-square test and Student\'s t test were performed to compare categorical and continuous variables among different groups of patients, respectively. Overall survival among different metastatic sites was analysed with Kaplan-Meier curves and log-rank test. Furthermore, we performed univariate and multivariate Cox proportional hazards models to identify other variables that might influence the prognosis. Statistical significance was considered at two-sided P value \< 0.05. All of statistical analyses were performed using statistical software package SPSS 20.0 (SPSS, Inc., Chicago, IL, USA).

Results
=======

Patients characteristics and metastasis pattern
-----------------------------------------------

From SEER database, we finally identified 8,677 patients who were diagnosed with primary liver cancer from 2010 to 2012. The detailed selection procedure of population was displayed in Figure [1](#F1){ref-type="fig"}. Primary liver cancer included 7681 hepatocellular carcinomas (88.5%), 986 intrahepatic cholangiocarcinoma (11.4%), 10 combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (0.1%). Baseline clinical characteristics of patients were presented in Table [1](#T1){ref-type="table"}. As shown in Table [1](#T1){ref-type="table"}, there were no significant differences of age, marital status, gender between metastasis and non-metastasis patients. Although intrahepatic cholangiocarcinoma consists a small part of liver cancer, ICC tended to be more likely to distant metastasis compared with HCC (36.4% vs*.* 18.4%, *P \< 0.01*). Patients with advanced stages received less surgery and more radiation therapy.

Among 8677 patients, there were 1775 patients at distant metastasis stages (20.5%) when they were diagnosed. Since the SEER only included metastatic site information related to lung, liver, bone, distant lymph and brain at the time of diagnosis, we focused on extrahepatic sites (lung, bone, distant lymph and brain) in further study. Detailed clinical features of extrahepatic metastatic patients were presented in [Supplementary Table](#SM1){ref-type="supplementary-material"} 1. The four extrahepatic metastatic sites accounted for 73.2% (1300/1775) of all advanced cases at the time of diagnosis. Lung was the most common metastatic site and brain was least common site, accounting for 36.2% (642/1775) and 1.9% (34/1775), respectively.

Distant metastasis pattern and combination of metastasis according to histology
-------------------------------------------------------------------------------

HCC and ICC were different in clinical features, therefore we analysed metastasis patterns according to histological subtypes. Since limited cases of combined HCC and ICC, we did not include this type for our analysis. The detailed clinical information of population with different histological subtypes was shown in [Supplementary Table](#SM1){ref-type="supplementary-material"} 2. For both HCC and ICC patients, lung and brain were still the most and least frequent extrahepatic metastatic sites, separately (Figure [2](#F2){ref-type="fig"}). However, several differences in extrahepatic metastatic patterns were existed between histological subtypes. Percentage of lung metastasis (38.4% vs. 27.6%, *P \< 0.05*), bone metastasis (32.6% vs. 18.9%, *P \< 0.05*), and distant lymph (24.6% VS 11.4%, *P \< 0.05*) were higher in HCC patients while there was no difference among incidence rate of brain metastasis between HCC and ICC (Figure [2](#F2){ref-type="fig"}).

Multiple metastatic sites were found in patients with HCC and ICC. Figure [3](#F3){ref-type="fig"} summarizes combinations of metastasis patterns according to histological subtypes. Among HCC, there were no differences among percentages of combinations of lung and any other metastasis site. A similar phenomenon was noted for bone metastasis, combined with any other metastasis site. In ICC patients, lung metastases were always frequently observed in combination with bone metastases and other two combinations (lung and brain, lung and distant lymph) were less common.

Survival analysis
-----------------

The survival difference associated with distant metastatic sites were illustrated by Figure [4](#F4){ref-type="fig"}. Since short duration of follow-up, we estimated the 1-year overall (OS) and cancer-specific survival (CSS) for patients with different extrahepatic metastases in current study. The 1-year OS was 15%, 13.7%, 10%, 5.9% for patients with bone, distant lymph, lung, brain metastasis, respectively. The 1-year CSS was 16.5%,14.8%, 12.6%, 6.3% for patients with bone, distant lymph, lung, brain metastasis, respectively. Furthermore, we performed univariate and multivariate Cox regression analysis to identify other variables that might influence the survival. We found that race, gender, age, marital status, histology, grade, and therapies could influence overall survival among patients with liver cancer (Table [2](#T2){ref-type="table"}). In addition, different extrahepatic metastatic sites were associated with distant risk of mortality (Table [3](#T3){ref-type="table"}). Compared with non-metastasis, patients with brain metastasis had the worst prognosis (OS, HR, 4.12, 95%CI, 2.92, 5.82; CSS, HR, 4.54, 95%CI, 3.20, 6.45). and patients with distant lymph metastasis had better survival rate (OS, HR, 2.17, 95%CI, 1.94, 2.42; CSS, HR, 2.36, 95%CI, 2.11, 2.64).

Relationship between metastatic status and survival across liver cancer by race, gender, marital status
-------------------------------------------------------------------------------------------------------

According to previous studies, race, gender, marital status-related discrepancies in prognosis of various cancer had been demonstrated. Therefore, we performed further analysis to examine whether these variables have different effects on association between metastatic status and survival rate. On multivariate overall survival analysis, the Black were found to have a significantly worst prognosis, compared with other racial groups (HR,1.39,95%1.14-1.71). Female who were under metastatic status have higher risk of mortality compared with male (HR,1.27,95%1.08-1.49). Regarding marital status, married patients have better survival than the unmarried (HR,1.37,95%1.21-1.55). Similar results were found in cancer-specific survival analysis.

Discussion
==========

Unlike other common cancers with reductions in the incidence and mortality, liver cancer shows unfavourable trends. The prognosis of liver cancer is still poor, particularly for advanced patients with 5-year relative survival rates of 3.1%^4^. A clear understanding of clinical features and metastatic sites becomes important essential. With enhanced imaging detection techniques, the reported incidence of extrahepatic metastases in patients with liver cancer is increasing. According to previous studies, the common location for extrahepatic metastasis from primary HCC include the lungs, lymph nodes, adrenal glands and bones^15-18^. The most common extrahepatic metastatic site is the lung, which was consistent with our studies. It was firstly reported by Lee et al.^13^ that three leading sites of hepatoma were lung, portal vein, and portal lymph node(s). In 2000, Katyal et al.^17^ reviewed 403 consecutive patients with HCC retrospectively and found that the lung, abdominal lymph nodes, and bone were the main sites of extrahepatic metastatic HCC. They also found that patients with more advanced intrahepatic tumour stage (stage IVA) at the diagnosis were more likely to occur extrahepatic metastases^17^. Another study conducted by Natsuizaka et al.^18^ showed that 73.8% of extrahepatic metastases patients had intrahepatic liver cancer at stage T3 or T4 according to the TNM classification and concluded that the precise evaluation of extrahepatic spread of HCC was crucial for appropriate treatment. However, few studies reported the common extrahepatic metastases for intrahepatic cholangiocarcinoma (ICC). Although the metastasis profile of ICC was similar with HCC, ICC showed a more invasive biological characteristic according to our studies. A better understanding of potential sites and clinical features of extrahepatic metastases may be crucial to determine appropriate therapies, which ultimately influence patients\' survival.

In the present study, we found that lung was the most common extrahepatic site for both HCC and ICC, followed by bone, distant lymph and brain. The main metastatic site of ICC is liver, whereas HCC was significantly more frequent to develop lung and bone metastasis than ICC. This suggested that we should pay more attention to extrahepatic metastasis of HCC patients. Furthermore, we analysed the survival rate and found that race, gender, age, marital status, histology, grade, and therapies were all significantly associated with OS. Besides, different extrahepatic metastatic sites also influenced overall and cancer-specific mortality. Sufficient treatments of both surgery and radiation therapies may improve prognosis even in advanced stage patients^19,\ 20^. Survival rate for patient with brain metastasis was worse than patients with bone metastasis. Hence, the presence of brain metastasis was an indicator of poor survival for primary liver cancer, although it was rare. Understanding of different extrahepatic metastatic sites was important for clinicians to adopt appropriate treatment choices. Furthermore, we observed that the Black, female, and unmarried patients had higher risk of mortality. Our study confirmed the association between biologic impacts with variables on prognosis of liver cancer, although the details are remains unclear).

To our knowledge, this is the first large population-based study from SEER to explore the extrahepatic metastasis of HCC and ICC, considering them as separate entities. We summarized metastatic patterns of HCC and ICC and analysed the impact of metastasis disparity on survival of liver cancer patients. However, several potential limitations of our study should be considered. First, it is important to note that we only included synchronous extrahepatic metastasis information. Some patients who would develop metachronous metastasis lesions were not included in our study, which might lead to underestimate extrahepatic metastasis of liver cancer. Furthermore, the database only provided limited metastatic sites but other extrahepatic metastatic sites (such as adrenal glands, peritoneum) were unclear. However, as we have noted, these four metastasis sites accounted for 73.2% of advanced liver cancer patients. Lastly, data related to chemotherapy was not available from SEER, which might influence survival analysis.

In conclusion, we found that both HCC and ICC patients present with similar extrahepatic metastatic patterns (lung, followed by bone, distant lymph and brain metastasis). Patients with distant lymph metastasis enjoyed best survival outcomes while patients with brain metastasis owned the worst prognosis in both OS and CSS analysis.

Supplementary Material {#SM0}
======================

###### 

Supplementary tables.

###### 

Click here for additional data file.
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###### 

Baseline clinical characteristics of primary liver cancer patients in SEER database

  Characteristic          No metastasis          Metastasis   P value          
  ----------------------- --------------- ------ ------------ --------- ------ ---------
  **Age**                                                                      0.333
  \<60                    2643            38.3                709       39.9   
  60-74                   3038            44.0                773       43.5   
  ≥75                     1221            17.7                293       16.5   
  **Marital status**                                                           
  Married                 3663            53.1                891       50.2   0.080
  Unmarried               2898            42.0                797       44.9   
  Unknown                 341             4.9                 87        4.9    
  **Race**                                                                     0.043
  White                   4680            67.8                1236      69.6   
  Black                   958             13.9                259       14.6   
  Other                   1264            18.3                280       15.8   
  **Gender**                                                                   0.178
  Male                    5138            74.4                1349      76.0   
  Female                  1764            25.6                426       24.0   
  **Histology**                                                                \<0.001
  HCC†                    6269            90.8                1412      79.5   
  ICC‡                    627             9.1                 359       20.2   
  Combined HCC and ICC    6               0.1                 4         0.2    
  **Grade**                                                                    \<0.001
  High                    1322            19.2                128       7.2    
  Moderate                2050            29.7                272       15.3   
  Poor                    881             12.8                286       16.1   
  Undifferentiation       62              0.9                 24        1.4    
  Unknown                 2587            37.5                1065      60.0   
  **Surgery therapy**                                                          \<0.001
  Surgery                 2887            41.8                94        5.3    
  No surgery              4001            58.0                1678      94.5   
  Unknown                 14              0.2                 3         0.2    
  **Radiation therapy**                                                        \<0.001
  Radiation               461             6.7                 304       17.1   
  No Radiation            6404            92.8                1465      82.5   
  Unknown                 37              0.5                 6         0.3    

Abbreviation: †, HCC, hepatocellular carcinoma; ‡, ICC, cholangiocarcinoma.

###### 

Univariate and multivariate overall survival analysis of liver cancer in SEER database

  Variable                Univariate analysis             Multivariate analysis                      
  ----------------------- --------------------- --------- ----------------------- ------------------ ---------
  **Race**                                                                                           
  White                   Reference                                               Reference          
  Black                   1.19 (1.11,1.28)      \<0.001                           1.12 (1.04,1.21)   0.002
  Other                   0.81 (0.75,0.87)      \<0.001                           0.89 (0.83,0.96)   0.002
  **Gender**                                                                                         
  Male                    Reference                                               Reference          
  Female                  0.93 (0.87,0.98)      0.011                             0.86(0.81,0.92)    \<0.001
  **Age**                                                                                            
  \<60                    Reference                                               Reference          
  60-74                   1.02 (0.97-1.09)      0.434                             1.02 (0.96-1.08)   0.600
  ≥75                     1.45 (1.35-1.56)      \<0.001                           1.29 (1.20-1.39)   \<0.001
  **Marital status**                                                                                 
  Married                 Reference                                               Reference          
  Unmarried               1.29 (1.22,1.36)      \<0.001                           1.19 (1.13,1.26)   0.000
  Unknown                 1.08 (0.96,1.23)      0.212                             1.02 (0.89,1.15)   0.820
  **Histology**                                                                                      
  HCC§                    Reference                                               Reference          
  ICC¶                    1.37 (1.27,1.48)      \<0.001                           1.28 (1.18,1.39)   0.000
  Combined HCC and ICC    0.71 (0.30,1.71)      0.448                             1.37 (0.57,3.30)   0.482
  **Grade**                                                                                          
  High                    Reference                                               Reference          
  Moderate                1.10 (1.00,1.20)      0.043                             1.31 (1.20,1.44)   \<0.001
  Poor                    1.99 (1.80,2.19)      \<0.001                           2.11 (1.91,2.33)   \<0.001
  Undifferentiation       2.38 (1.85,3.05)      \<0.001                           2.69(2.10,3.45)    \<0.001
  Unknown                 2.01 (1.85,2.18)      \<0.001                           1.56 (1.43,1.69)   \<0.001
  **Surgery therapy**                                                                                
  Surgery                 Reference                                               Reference          
  No surgery              4.84 (4.51,5.19)      \<0.001                           4.47 (4.16,4.81)   \<0.001
  Unknown                 5.36 (3.22,8.93)      \<0.001                           4.95 (2.97,8.25)   \<0.001
  **Radiation therapy**                                                                              
  Radiation               Reference                                               Reference          
  No Radiation            0.89 (0.82,0.97)      0.009                             1.20(1.10 1.31)    \<0.001
  Unknown                 1.11 (0.77,1.60)      0.567                             0.96(0.67,1.38)    0.837

Abbreviations: †, HR, hazard ratio; ‡, CI, confidence interval; §, HCC, hepatocellular carcinoma; ¶, ICC, cholangiocarcinoma.

###### 

Multivariate analysis of overall and cancer-specific survival in related to metastatic sites

  Variable               Overall survival              Cancer specific survival                       
  ---------------------- ------------------- --------- -------------------------- ------------------- ---------
  **No metastasis**      Reference                                                Reference           
  **Lung metastasis**    2.63 (2.40, 2.88)   \<0.001                              2.72 (2.48,2.99)    \<0.001
  **Bone metastasis**    2.31 (2.09, 2.56)   \<0.001                              2.47 (2.22, 2.75)   \<0.001
  **Distant lymph**      2.17 (1.94, 2.42)   \<0.001                              2.36 (2.11, 2.64)   \<0.001
  **Brain metastasis**   4.12 (2.92, 5.82)   \<0.001                              4.54 (3.20, 6.45)   \<0.001

\*Adjusted for race, gender, age, marital status, histology, grade, therapies.

Abbreviations: †, HR, hazard ratio; ‡, CI, confidence interval.

###### 

Relationship between metastatic status and survival across liver cancer by race, gender, marital status. (non-metastatic status as reference)

  -----------------------------------------------------------------------------------------------------
                       Multivariate analysis\   Multivariate analysis\                        
                       Overall survival         Cancer-specific survival                      
  -------------------- ------------------------ -------------------------- ------------------ ---------
  **Race**                                                                                    

  White                1.24 (1.12-1.37)         \<0.001                    1.20 (1.09-1.33)   \<0.001

  Black                1.39 (1.14-1.71)         0.001                      1.33 (1.07-1.64)   0.010

  Other                1.26 (1.04-1.54)         0.020                      1.20 (0.98-1.47)   0.084

  **Gender**                                                                                  

  Male                 1.26 (1.15-1.38)         \<0.001                    1.21 (1.10-1.33)   \<0.001

  Female               1.27 (1.08-1.49)         0.004                      1.24 (1.05-1.47)   0.013

  **Marital status**                                                                          

  Married              1.21 (1.08-1.36)         0.001                      1.17 (1.04-1.32)   0.010

  Unmarried            1.37 (1.21-1.55)         \<0.001                    1.32 (1.16-1.50)   \<0.001
  -----------------------------------------------------------------------------------------------------

\*Adjusted for age, grade, therapies.

Abbreviations: †, HR, hazard ratio; ‡, CI, confidence interval.
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